ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

Author:

Kwok Marwan12,Davies Nicholas1,Agathanggelou Angelo1,Smith Edward1,Oldreive Ceri1,Petermann Eva1,Stewart Grant1,Brown Jeff3,Lau Alan4,Pratt Guy15,Parry Helen12,Taylor Malcolm1,Moss Paul12,Hillmen Peter6,Stankovic Tatjana12

Affiliation:

1. School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom;

2. Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom;

3. Oncology iMed, AstraZeneca Pharmaceuticals, Waltham, MA;

4. R&D Oncology iMed, AstraZeneca Pharmaceuticals, Alderley Park, United Kingdom;

5. Birmingham Heartlands Hospital, Birmingham, United Kingdom; and

6. Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom

Abstract

Key PointsATR inhibition is synthetically lethal to TP53- or ATM-defective CLL cells. ATR targeting induces selective cytotoxicity and chemosensitization in TP53- or ATM-defective CLL cells in vitro and in vivo.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 209 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3